P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZED CLINICAL TRIALS (RCT)

• H. Erba,
• D. Pollyea,
• M. Sekeres,
• G. Garcia-Manero,
• K. Seiter,
• I. DeGutis,
• P. Kiselev,
• A. McBride,
• E. Yu,
• G. Roboz

Affiliations

H. Erba

1 Duke University, Durham

D. Pollyea

2 University of Colorado, Aurora

M. Sekeres

3 Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami

G. Garcia-Manero

4 The University of Texas MD Anderson Cancer Center, Houston

K. Seiter

5 New York Medical College, Valhalla

I. DeGutis

6 Bristol Myers Squibb, Princeton

P. Kiselev

6 Bristol Myers Squibb, Princeton

A. McBride

6 Bristol Myers Squibb, Princeton

E. Yu

6 Bristol Myers Squibb, Princeton

G. Roboz

7 Weill Cornell Medicine